公司于 2023 年 8 月 16 日收到控股股东傲农投资的通知，傲农投资于 2023 年 8 月 16 日与漳州金投就上述股份转让事宜签署《股份转让协议之补充协议》 （以下简称"补充协议"），就原协议第 7.1 条最后一款和第 7.2 条最后一款的 内容进行修订，现就原协议相关内容修订情况公告如下： 一、原协议第 7.1 条最后一款和第 7.2 条最后一款的内容 1、原协议第 7.1 条最后一款 发生卖方根本性违约事项时，买方有权选择继续履行本协议，亦有权通过向 证券代码：603363 证券简称：傲农生物 公告编号：2023-121 福建傲农生物科技集团股份有限公司 关于协议转让双方签署《股份转让协议之补充协议》 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 福建傲农生物科技集团股份有限公司（以下简称"公司"）控股股东厦门傲 农投资有限公司（以下简称"傲农投资"）为引进认可公司价值和看好公司未来 发展的国企战略投资者、优化公司股权结构，于 2023 年 7 月 11 日与漳州金投集 团有限公司（以下简称"漳州金投" ...

证券代码：603363 证券简称：傲农生物 公告编号：2023-120 公司收到问询函后，按照要求会同相关中介机构对问询函中的相关问题进行 了逐项落实，并对相关回复进行公开披露。具体内容详见公司 2023 年 7 月 22 日披露在上交所网站（www.sse.com.cn）的《关于福建傲农生物科技集团股份有 限公司向特定对象发行股票申请文件的第二轮审核问询函的回复》及其他相关文 件。 根据上交所的进一步审核意见，公司会同相关中介机构对部分回复内容进行 了补充与修订，具体内容详见公司同日在上交所网站（www.sse.com.cn）披露的 《关于福建傲农生物科技集团股份有限公司向特定对象发行股票申请文件的第 二轮审核问询函的回复（修订稿）》及其他相关文件。 公司本次向特定对象发行股票事项尚需通过上交所审核，并获得中国证券监 督管理委员会（以下简称"中国证监会"）做出同意注册的决定后方可实施，最 终能否通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存在不确 定性。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者注 意投资风险。 福建傲农生物科技集团股份有限公司 关于向特定对象发行股票申请文件 ...

向特定对象发行股票申请文件审核问询函中有关财 务会计问题的专项说明 福建傲农生物科技集团股份有限公司 容诚专字[2023]361Z0581 号 容诚会计师事务所(特殊普通合伙) 中国·北京 7-2-1 关于福建傲农生物科技集团股份有限公司 向特定对象发行股票申请文件审核问询函中 有关财务会计问题的专项说明 上海证券交易所： 贵所于 2023 年 7 月 6 日印发的《关于福建傲农生物科技集团股份有限公司 向特定对象发行股票申请文件的第二轮审核问询函》（上证上审（再融资）〔2023〕 453 号）（以下简称"审核问询函"）已收悉。福建傲农生物科技集团股份有限公 司（以下简称"傲农生物"、"公司"或"发行人"）与国泰君安证券股份有限公司（以 下简称"国泰君安"、"保荐机构"）、容诚会计师事务所（特殊普通合伙）（以下 简称"会计师"、"申报会计师"）、北京市中伦律师事务所（以下简称"发行人律 师"）等相关方对审核问询函所列示问题进行了逐项落实、核查。 现就本次审核问询函提出的问题书面回复如下，请予审核。 7-2-2 | 问题 | 1：关于经营情况 | 1 | | --- | --- | --- | | 问题 | 2 ...

7-1-1 上海证券交易所： 贵所于 2023 年 7 月 6 日印发的《关于福建傲农生物科技集团股份有限公司 向特定对象发行股票申请文件的第二轮审核问询函》（上证上审（再融资） 〔2023〕453 号）（以下简称"审核问询函"）已收悉。福建傲农生物科技集 团股份有限公司（以下简称"傲农生物"、"公司"或"发行人"）与国泰君 安证券股份有限公司（以下简称"国泰君安"、"保荐机构"）、容诚会计师 事务所（特殊普通合伙）（以下简称"会计师"、"申报会计师"）、北京市 中伦律师事务所（以下简称"发行人律师"）等相关方对审核问询函所列示问 题进行了逐项落实、核查。 现就本次审核问询函提出的问题书面回复如下，请予审核。 如无特别说明，本审核问询函回复所使用的简称与尽职调查报告中的释义 相同；以下回复中若出现各分项数值之和与总数尾数不符的情况，均为四舍五 入原因造成。 关于福建傲农生物科技集团股份有限公司向特定对 象发行股票申请文件的第二轮审核问询函的回复 保荐机构（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 本审核问询函回复中的字体格式说明如下： | 问询函所列问题 | 黑体加粗 | | --- | ...

北京市中伦律师事务所 关于福建傲农生物科技集团股份有限公司 向特定对象发行股票的 补充法律意见书（四） 7-3-1 | | | 补充法律意见书（四） 北京市朝阳区金和东路 20 号院正大中心 3 号楼南塔 22-31 层，邮编：100020 22-31/F, South Tower of CP Center, 20 Jin He East Avenue, Chaoyang District, Beijing 100020, P. R. China 电话/Tel：+86 10 5957 2288 传真/Fax：+86 10 6568 1022/1838 网址：www.zhonglun.com 北京市中伦律师事务所 关于福建傲农生物科技集团股份有限公司 二〇二三年八月 向特定对象发行股票的 补充法律意见书（四） 致：福建傲农生物科技集团股份有限公司 根据福建傲农生物科技集团股份有限公司（以下简称"发行人"、"公司"或"傲农 生物"，依上下文而定）与北京市中伦律师事务所（以下简称"本所"）签订的《法律顾 问聘用合同》，本所接受公司的委托，担任发行人 2022 年度向特定对象发行股票（以下 简称"本次发行"，依上下文 ...

证券代码：603363 证券简称：傲农生物 公告编号：2023-119 福建傲农生物科技集团股份有限公司 关于控股股东、实际控制人部分股份解除质押与质押 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司控股股东厦门傲农投资有限公司（以下简称"傲农投资"）持有本公 司股份总数为 310,153,069 股，占公司总股本的 35.61%。本次股份解除质押后， 傲农投资累计质押本公司股份 189,716,106 股，占其持有公司股份数的 61.17%， 占本公司总股本的 21.78%。 公司实际控制人吴有林先生持有本公司股份总数为 89,723,192 股，占公 司总股本的 10.30%。本次股份质押后，吴有林先生累计质押本公司股份 73,890,290 股，占其持有公司股份数的 82.35%，占本公司总股本的 8.48%。 一、 本次股份解除质押与质押的情况 福建傲农生物科技集团股份有限公司（以下简称"公司"或"本公司"）于近日 收到控股股东傲农投资、实际控制人吴有林先生关于办理部分股份解除质押与质 押 ...

福建傲农生物科技集团股份有限公司（以下简称"公司"或"本公司"）于近日 收到控股股东傲农投资关于办理部分股份解除质押与质押的通知，现将有关情况 公告如下： 1、本次股份解除质押的基本情况 | | | 证券代码：603363 证券简称：傲农生物 公告编号：2023-118 福建傲农生物科技集团股份有限公司 关于控股股东部分股份解除质押与质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司控股股东厦门傲农投资有限公司（以下简称"傲农投资"）持有本公 司股份总数为 310,153,069 股，占公司总股本的 35.61%。本次股份解除质押与质 押后，傲农投资累计质押本公司股份 208,416,106 股，占其持有公司股份数的 67.20%，占本公司总股本的 23.93%。 截至本公告披露日，傲农投资、吴有林先生及其一致行动人厦门裕泽投 资合伙企业（有限合伙）（以下简称"裕泽投资"）、吴有材先生、傅心锋先生、 张明浪先生、郭庆辉先生累计质押本公司股份 321,501,106 股，占控股股东、实 际控制人及其 ...

证券代码：603363 证券简称：傲农生物 公告编号：2023-061 福建傲农生物科技集团股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 5 月 19 日(星期五)至 5 月 25 日(星期四)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 anzq@aonong.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 福建傲农生物科技集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日在上海证券交易所网站（www.sse.com.cn）披露公司 2022 年度报告，为 便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计 划于 2023 年 5 月 26 日(星期五)下午 14:00-15:00 举行 2022 年度业绩暨现金分 红说明会，就投资者关心的问题进行交流。 本次 ...

Financial Performance - In 2022, the company reported a net profit attributable to shareholders of -1,039,026,342.02 RMB, marking a continuous loss for two consecutive years[4]. - The company plans not to distribute profits or increase capital from reserves in 2022, aiming to ensure sufficient operational funds for sustainable development[4]. - The cumulative undistributed profits at the end of the reporting period stood at 70,721,469.12 RMB[4]. - The company's operating revenue for 2022 was CNY 21,613,039,521.91, representing a 19.82% increase compared to CNY 18,038,160,160.78 in 2021[21]. - The net profit attributable to shareholders of the listed company for 2022 was CNY -1,039,026,342.02, an improvement from CNY -1,519,871,698.42 in 2021[21]. - The cash flow from operating activities for 2022 was CNY 663,636,691.19, which is a 26.58% increase from CNY 524,291,286.64 in 2021[21]. - The total assets at the end of 2022 were CNY 18,660,568,970.85, a 9.12% increase from CNY 17,100,526,968.06 at the end of 2021[21]. - The weighted average return on equity for 2022 was -49.79%, an increase of 24.29 percentage points from -74.08% in 2021[22]. - The company reported a basic earnings per share of CNY -1.34 for 2022, compared to CNY -2.34 in 2021[22]. - The net profit attributable to shareholders in the fourth quarter of 2022 was CNY -466,313,682.12, showing a decline from the third quarter's profit of CNY 104,028,083.90[24]. - The company experienced a significant increase in net assets, reaching CNY 2,503,834,737.32 at the end of 2022, up 92.09% from CNY 1,303,471,754.15 at the end of 2021[21]. - The total non-recurring gains and losses for 2022 amounted to CNY -39,873,166.83, compared to CNY -8,169,752.46 in 2021[27]. Operational Strategy - The company is in a critical phase of its second entrepreneurial venture, focusing on improving its capital structure and cash flow management[4]. - The company emphasizes the need for operational funds to support production and future growth amid industry cyclicality affecting the pig farming sector[4]. - The management has highlighted the importance of scale effects and efficiency, which have yet to be fully realized due to ongoing cost reductions in farming[4]. - The company is focusing on reducing breeding costs and improving management quality through enhanced biosecurity and health management practices[34]. - The company is actively expanding its food business in key provinces and cities, including establishing new slaughtering and processing bases in Fuzhou, Shandong, and Jiangxi[36]. - The company plans to divest its veterinary medicine and animal protection subsidiary to improve cash flow and focus on core business operations[37]. - The company aims to stabilize pork production capacity at around 55 million tons to prevent significant fluctuations in production[48]. - The company has established a breeding system with a target of producing 10 million pigs in the future, supported by sufficient breeding stock supply[51]. - The company is committed to innovation and aims to create a brand of green, safe, and nutritious pork products[52]. - The company is focused on achieving a comprehensive utilization rate of livestock manure exceeding 80% by 2025[48]. Market Position and Growth - The feed industry accounted for 53.89% of the company's main business revenue, while pig farming contributed 25.23%, and food processing accounted for 13.89%[38]. - The company has expanded its feed business to cover over 20 provinces and regions in China, becoming one of the largest feed manufacturers in the country[52]. - The company aims to achieve a pig output of 10 million heads by 2025, transitioning from a focus on quantity to improving quality and efficiency[60]. - The company's feed production capacity has reached over 7 million tons, with a mid-term goal of expanding to 10 million tons[60]. - The company is actively developing new slaughtering and food processing bases in Fuzhou, Binzhou, and Ji'an to enhance its operational scale[60]. - The company plans to enhance its slaughter and processing capacity in key pig farming regions to adapt to future competitive landscapes[123]. - The company aims to achieve a pig output of 6 million heads and feed sales of 400,000 tons in 2023, with a focus on improving operational efficiency and reducing costs[127]. Financial Management and Risks - The company has experienced an increase in debt ratio due to continuous expansion, necessitating a cautious approach to financial management[4]. - The company's asset-liability ratio stood at 81.61%, indicating a high level of leverage[71]. - The company is focusing on maintaining a balance between long-term and short-term financing to support its rapid growth and ensure sustainable development[129]. - The fluctuation in prices of key raw materials such as corn, soybean meal, and fish meal poses a significant risk to the company's operational costs and profitability[130]. - The cyclical nature of pig prices presents a risk of performance volatility, potentially impacting both pig farming and feed operations[131]. - The company is exploring pig futures as a strategy to mitigate risks associated with price fluctuations[132]. - The company has a high reliance on bank loans and commercial credit for working capital, which poses a risk if credit policies change[132]. Research and Development - The company is investing heavily in R&D, with a budget allocation of 62.94 million for the development of new technologies and products[145]. - The company has developed a comprehensive integrated service model around the pig industry, including feed, breeding, and food processing, which enhances overall value in the supply chain[69]. - The company holds 517 patents, including 122 invention patents, demonstrating its strong research and innovation capabilities[70]. - The company is developing key technologies for antibiotic alternatives in feed, currently in the pilot testing phase[91]. - The company is conducting research on the impact of different fat sources on the growth performance of freshwater fish, currently in the research phase[92]. - The company is developing a smart farming system for data analysis in pig farming, which is in the final development stage[92]. Environmental Responsibility - The company invested 71.12 million yuan in environmental protection during the reporting period[182]. - The company has established an environmental management system across its subsidiaries, ensuring compliance with national environmental protection laws[193]. - The company has implemented measures to reduce odor from pig farms, including regular cleaning and ventilation[194]. - The company is committed to sustainable development and has upgraded its environmental facilities to enhance pollution prevention measures[196]. - The company completed 2 technology patents in 2022, focusing on sludge and odor treatment as common industry issues[198]. - The company has established emergency response plans for environmental incidents, enhancing staff training and preparedness[187]. Corporate Governance - The company has established a sound organizational structure independent of the controlling shareholder, ensuring independent business decision-making[141]. - The company approved several resolutions at the 2022 annual general meeting, including the financial budget for 2022 and the profit distribution plan for 2021[141]. - The audit committee consists of Liu Feng, Zheng Luying, and Ye Junbiao, ensuring oversight of financial reporting and compliance[157]. - The company has established a mechanism for timely information disclosure from subsidiaries to ensure compliance with disclosure regulations[177]. - The company emphasizes investor relations management to enhance transparency and communication with investors[139].